STOCK TITAN

Liquidia Corporation - LQDA STOCK NEWS

Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.

Overview

Liquidia Corporation (LQDA) is a United States-based biopharmaceutical company dedicated to transforming therapy development for pulmonary hypertension and other rare cardiopulmonary diseases. Utilizing its proprietary PRINT® Technology, the company engineers precise, uniform drug particles to optimize drug delivery and improve treatment efficacy. This innovative approach addresses critical gaps in current therapeutic options, ensuring products are manufactured under scalable, cGMP-compliant processes.

Core Technology and Business Model

At its core, Liquidia harnesses the power of PRINT® Technology to overcome common challenges in drug delivery. By producing highly controlled and uniform particles, the company enhances deposition in the lungs, which is vital for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s model includes both the advancement of its own pipeline and strategic licensing of its technology to globally recognized pharmaceutical partners.

Product Portfolio and Clinical Focus

Liquidia’s primary product candidate, YUTREPIA™ (treprostinil) inhalation powder, exemplifies its application of precision particle engineering for the treatment of PAH and PH-ILD. The company is also developing additional candidates and formulations, including a sustained-release liposomal version designed for twice-daily administration, further diversifying its clinical offerings. This broad clinical focus reinforces Liquidia’s commitment to addressing unmet patient needs.

Market Position and Competitive Landscape

Positioned in a competitive biopharmaceutical landscape, Liquidia distinguishes itself through its unique technological platform and rigorous adherence to quality standards. Its scalable PRINT® process, combined with robust clinical research and strategic partnerships, offers a scientifically sound alternative in a market with significant unmet needs. Industry-specific terms such as "drug particle engineering", "inhaled therapeutics", and "cGMP compliance" attest to the company’s technical expertise and operational rigor.

Operational Excellence and Regulatory Focus

Liquidia’s operations are streamlined across its specialized subsidiaries, ensuring efficient research, development, and commercialization processes. The company maintains a strict focus on quality by aligning its manufacturing practices with the highest regulatory standards, hence building a foundation of trust and reliability in its product offerings. This diligence in quality control and regulatory adherence solidifies its reputation within the oncology and pulmonary care communities.

Industry Collaboration and Strategic Partnerships

Liquidia actively collaborates with major pharmaceutical entities, both to license its PRINT® platform and to accelerate the commercialization of its products. These partnerships allow for a mutual exchange of expertise and resources, further enhancing its market reach and ensuring that advanced therapies are delivered efficiently. Such strategic alliances are critical for fostering innovation and establishing a competitive advantage in the complex healthcare landscape.

Commitment to Innovation and Quality

With a commitment to continuous innovation, Liquidia leverages extensive clinical studies and state-of-the-art manufacturing processes to bring safer and more effective treatment options to patients. Emphasizing precision in every phase of development, the company sets itself apart by ensuring that its therapies are optimally designed to tackle the challenges of pulmonary hypertension and related ailments.

Rhea-AI Summary

Liquidia Technologies (LQDA) has received FDA acceptance for its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH), with a Prescription Drug User Fee Act (PDUFA) goal date set for November 24, 2020. The company reported no revenues for Q2 2020, a decrease from $8.1 million in Q2 2019, resulting in a net loss of $13.9 million. R&D expenses decreased while G&A expenses rose significantly due to legal costs associated with the RareGen acquisition. Liquidia raised $75 million from a public offering and appointed Tushar Shah, M.D. as Chief Medical Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
-
Rhea-AI Summary

Liquidia Technologies (Nasdaq: LQDA) will have its CEO, Neal Fowler, present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:20 AM ET. The event will highlight Liquidia's focus on developing novel biopharmaceutical products using its proprietary PRINT® technology, aimed at enhancing patient outcomes. Liquidia is currently developing two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for postoperative pain. A live audio webcast will be available for attendees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences
-
Rhea-AI Summary

Liquidia Technologies (LQDA) reported exploratory endpoint data from the INSPIRE study of LIQ861 for pulmonary arterial hypertension (PAH) during the ATS Annual Meeting. LIQ861, an inhaled dry powder formulation, showed improvements after two months, including increased six-minute walk distance and reduced Minnesota LIVING WITH HEART FAILURE Questionnaire scores. Over 70% of subjects titrated to higher doses, with 93% tolerating the treatment well. Liquidia has submitted a New Drug Application for LIQ861, awaiting FDA review by November 24, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
Rhea-AI Summary

Liquidia Technologies (Nasdaq: LQDA) announced plans to release its second quarter 2020 financial results on August 10, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. The company focuses on developing novel therapeutics using its proprietary PRINT® technology, primarily targeting pulmonary arterial hypertension (PAH) with its product candidate LIQ861 and local post-operative pain with LIQ865. Liquidia aims to improve patient outcomes through precise drug particle production.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
conferences earnings
-
Rhea-AI Summary

Liquidia Technologies (LQDA) announced an amended complaint from United Therapeutics Corporation regarding alleged patent infringement related to its pulmonary arterial hypertension treatment, LIQ861. The original complaint, filed in June 2020, triggered a 30-month regulatory stay on LIQ861's FDA approval. However, the new patent allegations do not affect the review timeline. Liquidia asserts that LIQ861 offers a beneficial treatment option for patients, and the company is committed to defending its position vigorously.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
none
-
Rhea-AI Summary

Liquidia Technologies (NASDAQ: LQDA) has successfully closed a public offering of 9,375,000 shares at $8.00 each, generating total gross proceeds of $75 million. This offering follows a previously filed registration statement with the SEC. The underwriters have a 30-day option to purchase an additional 1,406,250 shares. Jefferies acted as the sole book-running manager with Needham & Company and Wedbush PacGrow as co-managers. The securities will not be offered where prohibited by state laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary

Liquidia Technologies (NASDAQ: LQDA) will host a webcast and conference call on June 30, 2020, at 8:00 a.m. ET to discuss updates regarding the proposed acquisition of RareGen and an ongoing common stock offering. Investors can join via domestic dial-in (1-877-707-8711) or international dial-in (1-857-270-6219) using passcode 4836889. Liquidia focuses on innovative drug delivery via PRINT® technology, targeting conditions like pulmonary arterial hypertension (LIQ861) and post-operative pain (LIQ865). For more details, visit Liquidia's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.09%
Tags
conferences
-
Rhea-AI Summary

Liquidia Technologies, Inc. (NASDAQ: LQDA) announced a public offering of 9,375,000 shares of common stock at $8.00 each, yielding gross proceeds of $75 million. This offering is solely by Liquidia, with a 30-day option for underwriters to purchase an additional 1,406,250 shares. The transaction is expected to close on July 2, 2020. Jefferies serves as the sole book-running manager. The offering is conducted under a shelf registration statement declared effective by the SEC in September 2019, and related documents can be accessed via the SEC website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.09%
Tags
-
Rhea-AI Summary

Liquidia Technologies (NASDAQ: LQDA) has announced its acquisition of RareGen, LLC, enhancing its capabilities in pulmonary arterial hypertension (PAH) treatment. The all-stock merger, expected to close in Q4 2020, will create Liquidia Corporation and allow it to promote RareGen's generic treprostinil. This strategic move is aimed at improving the company's commercial readiness for LIQ861, an inhaled treatment for PAH. The merger is set to bolster Liquidia's market presence, integrating RareGen's sales force and expertise in rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.09%
Tags
Rhea-AI Summary

Liquidia Technologies (LQDA) has announced a patent infringement lawsuit filed by United Therapeutics Corporation against it, relating to its New Drug Application (NDA) for LIQ861, a dry powder inhalation of treprostinil for pulmonary arterial hypertension (PAH). The case, filed under the Hatch-Waxman Act, could delay FDA approval of LIQ861 by up to 30 months. Liquidia asserts that the patents are either invalid or not infringed and intends to defend against the suit vigorously. The company has previously filed petitions for inter partes review of the patents, with a decision expected by Q3 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.08%
Tags
none

FAQ

What is the current stock price of Liquidia Corporation (LQDA)?

The current stock price of Liquidia Corporation (LQDA) is $14.52 as of April 2, 2025.

What is the market cap of Liquidia Corporation (LQDA)?

The market cap of Liquidia Corporation (LQDA) is approximately 1.2B.

What is Liquidia Corporation's core business?

Liquidia Corporation develops innovative therapies for pulmonary hypertension and other rare cardiopulmonary diseases using its proprietary PRINT® Technology for precise drug particle engineering.

How does PRINT® Technology enhance drug delivery?

PRINT® Technology enables the scalable production of uniform drug particles, ensuring optimal deposition in the lungs and improved efficacy for inhaled therapeutics.

Which therapeutic areas does Liquidia focus on?

The company primarily focuses on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), addressing significant unmet patient needs.

How does Liquidia generate revenue?

Liquidia generates revenue through the development of its own product candidates and by licensing its innovative PRINT® Technology to global pharmaceutical partners.

What differentiates Liquidia from its competitors?

Liquidia’s unique PRINT® Technology, enabling precise and scalable drug particle engineering, combined with its focus on quality and regulatory compliance, sets it apart in the biopharmaceutical sector.

How does Liquidia ensure the quality and safety of its products?

The company adheres to stringent cGMP-compliant processes and maintains robust regulatory oversight, ensuring that all products meet high quality and safety standards.

What role do strategic partnerships play in Liquidia’s business model?

Strategic partnerships allow Liquidia to leverage external expertise and resources, enhancing the development and commercialization of its innovative therapies and expanding its market reach.
Liquidia Corporation

Nasdaq:LQDA

LQDA Rankings

LQDA Stock Data

1.24B
71.19M
13.88%
61.4%
13.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE